Phase 1/2 study

Waltham, Massachusetts, USA, April 6, 2026 Health Canada Approval Marks Key Clinical Milestone In a significant development for cardiovascular...

Amsterdam, Netherlands | February 9 2026 — Vectory Therapeutics has announced that the first participant has been dosed in...

WALTHAM, Mass. & SHANGHAI, Feb. 2, 2026 — Ensem Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, announced that it...